BIOMARIN TAKES $283M CHARGE ON ALESTA DEAL

BioMarin disclosed in an SEC filing that the Alesta Therapeutics acquisition will cut Q3 2026 earnings by $283 million in IPR&D expense, a $1.50 hit to both GAAP and non-GAAP diluted EPS. That is nearly all of the $320 million in total charges the deal will bring for full-year 2026. $BMRN will update guidance alongside third-quarter results.